A small clarification. Section 27(a)(5)'s definition of "generic drug" was tightened to explicitly state that a (b)(2) application seeks therapeutic equivalence to the "reference product abbreviated new drug application." A minor punctuation correction was also made in Section 27(b)(3)(A).
Drug Competition Enhancement Act
- Sponsor
- Sen. Cornyn, John [R-TX]
- Committees
- Judiciary Committee (primary)
- Last action
- Apr 10, 2025
Bottom line
The bill aims to enhance competition in the pharmaceutical market by preventing brand-name drug manufacturers from using product reformulations to delay the entry of lower-cost generic and biosimilar alternatives.
What it actually does
This bill amends the Federal Trade Commission Act to explicitly prohibit 'product hopping' by pharmaceutical manufacturers. It defines product hopping as a manufacturer of a reference drug or listed drug making changes or reformulations to their product (a 'follow-on product') while simultaneously taking actions to disadvantage the original product, thereby impeding competition from generic or biosimilar versions. The bill outlines specific conditions for 'hard switches' and 'soft switches' and provides a framework for manufacturers to justify their actions based on safety, supply, or legitimate pro-competitive reasons, which the FTC can then challenge.
Proponents argue
Supporters argue that product hopping is an anticompetitive tactic used by brand-name drug manufacturers to extend market exclusivity and prevent generic or biosimilar competition, ultimately driving up drug costs for consumers and healthcare systems. They contend that this bill provides the Federal Trade Commission with a clear statutory tool to combat such practices, ensuring that patients have access to more affordable medications sooner. Proponents highlight that the bill includes carve-outs for legitimate safety or supply chain issues, ensuring that necessary product changes are not unduly penalized.
Opponents contend
Opponents, typically representing brand-name pharmaceutical manufacturers, might argue that the bill could stifle innovation by penalizing legitimate product improvements or reformulations. They may contend that manufacturers should have the flexibility to update their products to improve patient outcomes or convenience without facing antitrust scrutiny, and that new formulations can offer real benefits. Critics might also express concern that the bill's definitions of 'hard switch' and 'soft switch' are overly broad or could lead to subjective enforcement, creating regulatory uncertainty and potentially chilling investment in drug development.
The bill is moderately complex due to its legal definitions and specific conditions, requiring careful reading to understand its full scope. The estimated reading time of 15-20 minutes is reasonable for an informed reader to grasp its implications.
Section 2(a), adding new Section 27(a) to the FTC Act
Definitions for Product Hopping Prohibition
This section establishes key definitions for terms central to the bill, such as "abbreviated new drug application" (ANDA), "biosimilar biological product," "follow-on product," "generic drug," "listed drug," and "manufacturer." Crucially, "follow-on product" is defined as a modification or reformulation of a manufacturer's existing drug with a similar indication, excluding changes requested by the Secretary or necessary for legal compliance. These definitions set the scope for what actions constitute product hopping.
Supporters argue
Supporters argue that precise definitions are essential to ensure the law is clear, enforceable, and targets the specific anticompetitive practices of product hopping without inadvertently penalizing legitimate innovation.
Critics contend
Opponents might argue that some definitions, particularly "follow-on product," could be interpreted too broadly, potentially encompassing beneficial product improvements and subjecting them to undue scrutiny.
Tradeoffs
Balancing the need for clear legal definitions to prevent anticompetitive behavior against the risk of inadvertently stifling legitimate product innovation or improvements.
Section 2(a), adding new Section 27(b)(1)(A) to the FTC Act
Prohibition on "Hard Switches"
This provision defines and prohibits "hard switches," a form of product hopping where a manufacturer intentionally removes an original drug from the market to force patients and prescribers to switch to a new, often slightly modified, version of the drug. This is established if the manufacturer requested FDA to withdraw approval or list the drug as discontinued, and marketed a follow-on product. It also covers situations where a manufacturer withdraws, discontinues manufacture, or destroys inventory of the original drug in a manner that impedes generic/biosimilar competition, while also marketing a follow-on product.
Section 2(a), adding new Section 27(b)(1)(B) to the FTC Act
Prohibition on "Soft Switches"
This provision addresses "soft switches," where a manufacturer takes actions (other than those constituting a hard switch) that unfairly disadvantage the original drug relative to its follow-on product, thereby impeding generic or biosimilar competition, while also marketing the follow-on product. This could include subtle marketing shifts, changes in rebate structures, or other commercial strategies designed to steer patients and prescribers away from the original drug and towards the new version, making it harder for generics to gain traction.
Section 2(a), adding new Section 27(b)(3) and (4) to the FTC Act
Justifications and Rebuttals for Product Hopping Actions
This section allows a manufacturer accused of product hopping to offer justifications for their actions. For a hard switch, justifications include safety risks or uncontrollable supply disruptions. For a soft switch, manufacturers must demonstrate legitimate pro-competitive reasons apart from reduced competition's financial effects. The FTC can then rebut these justifications or argue that the pro-competitive benefits do not outweigh anticompetitive effects, or that less anticompetitive means exist to achieve the stated justifications.
Section 2(a), adding new Section 27(c) to the FTC Act
Federal Trade Commission Enforcement Powers
This section grants the Federal Trade Commission (FTC) specific powers to enforce the product hopping prohibition. The FTC can initiate administrative proceedings, seek temporary injunctions in federal court, or bring suit for permanent injunctions and equitable remedies. These remedies include disgorgement of unjust enrichment (within a 5-year limitation period) and restitution. The section also outlines judicial review procedures for final cease and desist orders.
Excludes certain changes or reformulations from the definition of a "follow-on product" if they are requested by the Secretary (of HHS) or necessary to comply with laws like sections 505A and 505B of the Federal Food, Drug, and Cosmetic Act (related to pediatric exclusivity and rare pediatric disease priority review vouchers).
Section 2(a), new Section 27(a)(4)(B)
Why it matters:This is standard legislative practice to ensure that the primary definition is clear, with specific exceptions detailed within. It's not necessarily evasive but requires careful reading.
Case for: Proponents would argue this carve-out is essential to ensure that manufacturers are not penalized for making product changes that are legally mandated or encouraged for public health reasons (e.g., pediatric studies), even if those changes result in a new formulation.
Case against: Critics might argue that such carve-outs could be exploited if the "request by the Secretary" or "necessary to comply with law" clauses are interpreted too broadly, potentially allowing some forms of product hopping to escape scrutiny under the guise of compliance.
Estimated impact: Ensures that specific, policy-driven product changes (like those for pediatric populations) are protected from product hopping allegations, potentially preserving incentives for such research.
Specifies the "period" during which product hopping actions are prohibited: "beginning on the date on which the manufacturer... first receives notice that an applicant has submitted... an abbreviated new drug application or biosimilar biological product license application... and ending on the date that is the earlier of 180 days after the date on which the generic drug or biosimilar biological product... is first marketed or 3 years after the date on which the follow-on product is first marketed."
Section 2(a), new Section 27(b)(1) (introductory clause)
Why it matters:This is typical for defining the temporal scope of a prohibition. It's complex because it involves multiple potential trigger dates.
Case for: Proponents would argue that defining a clear, limited window for the prohibition is crucial. It focuses enforcement on the period when anticompetitive product hopping is most likely to occur and have the greatest impact on generic/biosimilar entry, while not indefinitely restricting manufacturer actions.
Case against: Critics might argue that the 3-year window after a follow-on product is marketed could still be too long or too short depending on the specific drug and market dynamics, potentially either allowing some anticompetitive behavior to escape or unduly restricting legitimate actions.
Estimated impact: Defines the critical window of vulnerability for generic/biosimilar entry, directly impacting the timing of market competition.